A UK femtech startup just raised $9 million to solve one of healthcare's most overlooked data gaps. Emm's smart menstrual cup uses embedded sensors to track reproductive health patterns that could revolutionize diagnosis of conditions like endometriosis, which typically takes 7-10 years to identify. With 30,000 pre-orders already secured, the company plans to launch commercially in 2026.
Emm founder Jenny Button had her breakthrough moment during COVID lockdown. She was wearing an Oura ring and Whoop band, getting detailed insights about sleep and fitness, but realized something was missing from the wearables ecosystem. "It seemed crazy to me, because these are things that every woman wants to be able to track and better understand," Button told TechCrunch. The obvious gap? Reproductive and menstrual health data.
Five years and thousands of design iterations later, Emm just closed a $9 million seed round led by Lunar Ventures to bring what the company calls "the world's first smart menstrual cup" to market in 2026. The funding (£6.8 million) also includes Alumni Ventures - the same firm that backed Oura - and BlueLion Global.
The timing couldn't be better for femtech investors looking for the next breakthrough. While period-tracking apps have dominated the space, actual hardware that can gather biological data has remained virtually untapped. Emm's medical-grade silicone cup contains "ultra-thin, advanced sensor technology" that analyzes menstrual blood to detect patterns about users' reproductive cycles.
But this isn't just about convenience - it's about solving a massive healthcare blind spot. One in ten women suffers from endometriosis, according to Button's research, yet diagnosis typically takes seven to ten years. "That delay is largely due to the lack of meaningful data and poor characterization of menstrual health in clinical settings," Button explained. "There have been no reliable tools to accurately and objectively track that aspect of health until now."
The broader market opportunity is staggering. UK government data shows one in three women experiences severe reproductive health issues throughout their lives. Other femtech founders recently told The Guardian that menstrual blood represents an "overlooked opportunity in women's health" that could offer insights unavailable from traditional blood tests.
Emm's approach mirrors the successful playbook of other health wearables - collect continuous data, identify patterns, and provide actionable insights. The company has already secured 30,000 pre-orders, suggesting strong consumer demand for this type of reproductive health monitoring. Data collected through the Emm app gets encrypted and stored with two-factor authentication, with personal identifiers anonymized or pseudonymized.
Button described the funding round as "strategic," connecting with lead investor Lunar Ventures through her network. The capital will fund the UK market launch next year, with research and development taking priority as the team prepares for US market entry in early 2027.
The competitive landscape remains wide open. While companies like Apple have added period tracking to the Apple Watch and various apps track symptoms, no major player has tackled hardware-based menstrual health monitoring. This gives Emm a potential first-mover advantage in what could become a significant new category within the broader $50 billion femtech market.
"Menstrual health is only the jumping off point for Emm," Button said, outlining ambitious expansion plans that could include diagnosis tools, digital care platforms, and even therapeutics. "Our mission is to accelerate diagnosis, equip people with the data to advocate for themselves, and ultimately help them take control of their own bodies and health journeys."
For investors, Emm represents a rare opportunity to back hardware innovation in an underserved market with clear consumer demand and massive health impact potential. The fact that Alumni Ventures - which has seen success with Oura's rise to a multi-billion dollar valuation - is backing the company suggests confidence that smart health monitoring is expanding beyond fitness into reproductive wellness.
Emm's $9 million raise signals that investors are finally ready to tackle reproductive health's hardware gap. With 30,000 pre-orders secured and a clear path to market, the company could pioneer an entirely new category of health monitoring devices. If successful, Emm won't just track periods - it could fundamentally change how conditions like endometriosis get diagnosed and treated, potentially saving millions of women years of medical uncertainty.
